Publications by authors named "F Takatsu"
Article Synopsis
- The study focuses on understanding how lung cancer cells develop resistance to crizotinib, a MET tyrosine kinase inhibitor, particularly in cases of MET amplification.
- Researchers established two MET-amplified lung cancer cell lines, EBC-1 and H1993, to explore the mechanisms behind this acquired resistance, using genomic and transcriptomic data for analysis.
- Findings revealed various resistance mechanisms, including SERPINE1 overexpression in EBC-1 cells and potential therapies like PAI-1 inhibitors or MEK inhibitors for overcoming resistance in these cancer cells.
Article Synopsis
- CAF-derived POSTN is significantly overexpressed in non-small cell lung cancer (NSCLC) compared to normal fibroblasts, contributing to tumor growth and progression.
- POSTN promotes cell proliferation and enhances the ability of NSCLC cells to undergo epithelial-mesenchymal transition (EMT) through activation of the ERK signaling pathway.
- Knocking down POSTN in cancer-associated fibroblasts improves the effectiveness of osimertinib treatment in EGFR-mutant NSCLC cells, suggesting that targeting POSTN could be a promising therapeutic approach.
Background: Tumor-produced high molecular weight insulin-like growth factor-II (big insulin-like growth factor-II) is considered to cause non-islet cell tumor hypoglycemia. This paper presents a case of surgically resected retroperitoneal liposarcoma that produced big insulin-like growth factor-II.
Case Presentation: Here, we report the case of a 62-year-old woman who presented with an abdominal mass and hypoglycemia.
Article Synopsis
- Cancer-associated fibroblasts (CAFs) play a key role in helping cancer cells resist treatment, particularly in non-small cell lung cancer (NSCLC), by fostering a supportive tumor environment.
- Tranilast, an antiallergic medication, was shown to reduce cytokine release from CAFs, affecting their interaction with NSCLC cells and mitigating drug resistance.
- The study found that using tranilast alongside targeted therapy not only counteracted the protective effects of CAFs but also reversed resistance to drugs like osimertinib and selumetinib in NSCLC cells.